治疗慢性肾脏疾病相关性贫血的新药:daprodustat  

A new drug in treatment of chronic kidney disease-associated anemia:daprodustat

作　　者：席敦香 巩萍[2] XI Dun-xiang;GONG Ping(Department of Blood Purification,the People's Hospital of Linqu,Linqu SHANDONG 262600,China;Department of Pharmacy,the People's Hospital of Linqu,Linqu SHANDONG 262600,China)

机构地区：[1]临朐县人民医院血液净化科,山东临朐262600 [2]临朐县人民医院药剂科,山东临朐262600

出　　处：《中国新药与临床杂志》2018年第11期612-615,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：贫血是晚期慢性肾脏疾病(CKD)的主要症状之一,严重损害患者的生活质量。daprodustat是一种新型的口服脯氨酰羟化酶抑制剂,能稳定低氧诱导因子,刺激内源性促红细胞生成素释放进而促进红细胞的增殖。临床试验表明, daprodustat对透析和非透析患者的CKD相关性贫血有显著疗效,与促红细胞生成素相比可更有效地维持体内血红蛋白水平的稳定,也能减小心血管事件的发生率。此外,daprodustat的不良反应少、患者耐受性和依从性良好。Anemia is one of the typical symptoms of advanced chronic kidney disease (CKD),leading the patients to a lower quality of life.Daprodustat,a novel oral prolyl hydroxylase inhibitor,can stabilize hypoxia inducible factor as to stimulate the release of endogenous erythropoietin and promote the proliferation of erythrocyte.Clinical trials have shown that daprodustat is effectively in treating CKD-associated anemia of non- dialysis or dialysis patients.Especially,unlike traditional erythropoiesis-stimulating agents,the daprodustat not only stabilizes the physiological concentrations of erythropoietin and hemoglobin but also reduce the risk of cardiovascular events.In addition,daprodustat causes few adverse reactions as well as imparts patients the fine tolerability and compliance.

关 键 词：daprodustat 贫血 肾功能不全 慢性 慢性肾脏疾病 脯氨酰羟化酶抑制剂 

分 类 号：R556[医药卫生—血液循环系统疾病] R973[医药卫生—内科学]